



**ICH Topic E 6 (R1)  
Guideline for Good Clinical Practice**

**Step 5**

**NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE  
(CPMP/ICH/135/95)**

TRANSMISSION TO CPMP	July 1996
FINAL APPROVAL BY CPMP	July 1996
DATE FOR COMING INTO OPERATION	January 1997
POST STEP ERRATA (linguistic minor corrections)	July 2002

## TABLE OF CONTENT

<b>INTRODUCTION</b> .....	<b>5</b>
<b>1. GLOSSARY</b> .....	<b>5</b>
1.1 ADVERSE DRUG REACTION (ADR) .....	5
1.2 ADVERSE EVENT (AE).....	5
1.3 AMENDMENT (TO THE PROTOCOL).....	5
1.4 APPLICABLE REGULATORY REQUIREMENT(S) .....	5
1.5 APPROVAL (IN RELATION TO INSTITUTIONAL REVIEW BOARDS) .....	5
1.6 AUDIT .....	5
1.7 AUDIT CERTIFICATE .....	6
1.8 AUDIT REPORT .....	6
1.9 AUDIT TRAIL .....	6
1.10 BLINDING/MASKING.....	6
1.11 CASE REPORT FORM (CRF).....	6
1.12 CLINICAL TRIAL/STUDY .....	6
1.13 CLINICAL TRIAL/STUDY REPORT.....	6
1.14 COMPARATOR (PRODUCT).....	6
1.15 COMPLIANCE (IN RELATION TO TRIALS).....	6
1.16 CONFIDENTIALITY .....	6
1.17 CONTRACT.....	6
1.18 COORDINATING COMMITTEE .....	6
1.19 COORDINATING INVESTIGATOR .....	7
1.20 CONTRACT RESEARCH ORGANIZATION (CRO).....	7
1.21 DIRECT ACCESS.....	7
1.22 DOCUMENTATION .....	7
1.23 ESSENTIAL DOCUMENTS.....	7
1.24 GOOD CLINICAL PRACTICE (GCP).....	7
1.25 INDEPENDENT DATA-MONITORING COMMITTEE (IDMC) (DATA AND SAFETY MONITORING BOARD, MONITORING COMMITTEE, DATA MONITORING COMMITTEE).....	7
1.26 IMPARTIAL WITNESS .....	7
1.27 INDEPENDENT ETHICS COMMITTEE (IEC).....	7
1.28 INFORMED CONSENT .....	8
1.29 INSPECTION .....	8
1.30 INSTITUTION (MEDICAL) .....	8
1.31 INSTITUTIONAL REVIEW BOARD (IRB).....	8
1.32 INTERIM CLINICAL TRIAL/STUDY REPORT .....	8
1.33 INVESTIGATIONAL PRODUCT .....	8
1.34 INVESTIGATOR.....	8
1.35 INVESTIGATOR / INSTITUTION .....	8
1.36 INVESTIGATOR'S BROCHURE.....	8
1.37 LEGALLY ACCEPTABLE REPRESENTATIVE.....	8
1.38 MONITORING .....	9
1.39 MONITORING REPORT.....	9
1.40 MULTICENTRE TRIAL.....	9
1.41 NONCLINICAL STUDY .....	9
1.42 OPINION (IN RELATION TO INDEPENDENT ETHICS COMMITTEE).....	9
1.43 ORIGINAL MEDICAL RECORD .....	9
1.44 PROTOCOL .....	9
1.45 PROTOCOL AMENDMENT .....	9

1.46	QUALITY ASSURANCE (QA).....	9
1.47	QUALITY CONTROL (QC).....	9
1.48	RANDOMIZATION .....	9
1.49	REGULATORY AUTHORITIES.....	9
1.50	SERIOUS ADVERSE EVENT (SAE) OR SERIOUS ADVERSE DRUG REACTION (SERIOUS ADR) 9	
1.51	SOURCE DATA.....	10
1.52	SOURCE DOCUMENTS .....	10
1.53	SPONSOR .....	10
1.54	SPONSOR-INVESTIGATOR .....	10
1.55	STANDARD OPERATING PROCEDURES (SOPs).....	10
1.56	SUBINVESTIGATOR .....	10
1.57	SUBJECT/TRIAL SUBJECT.....	10
1.58	SUBJECT IDENTIFICATION CODE.....	10
1.59	TRIAL SITE .....	10
1.60	UNEXPECTED ADVERSE DRUG REACTION.....	10
1.61	VULNERABLE SUBJECTS .....	11
1.62	WELL-BEING (OF THE TRIAL SUBJECTS).....	11
<b>2.</b>	<b>THE PRINCIPLES OF ICH GCP .....</b>	<b>11</b>
<b>3.</b>	<b>INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC).....</b>	<b>12</b>
3.1	RESPONSIBILITIES.....	12
3.2	COMPOSITION, FUNCTIONS AND OPERATIONS .....	13
3.3	PROCEDURES .....	13
3.4	RECORDS.....	14
<b>4.</b>	<b>INVESTIGATOR .....</b>	<b>14</b>
4.1	INVESTIGATOR'S QUALIFICATIONS AND AGREEMENTS.....	14
4.2	ADEQUATE RESOURCES .....	15
4.3	MEDICAL CARE OF TRIAL SUBJECTS .....	15
4.4	COMMUNICATION WITH IRB/IEC.....	15
4.5	COMPLIANCE WITH PROTOCOL.....	16
4.6	INVESTIGATIONAL PRODUCT(S).....	16
4.7	RANDOMIZATION PROCEDURES AND UNBLINDING.....	17
4.8	INFORMED CONSENT OF TRIAL SUBJECTS .....	17
4.9	RECORDS AND REPORTS .....	20
4.10	PROGRESS REPORTS .....	20
4.11	SAFETY REPORTING .....	20
4.12	PREMATURE TERMINATION OR SUSPENSION OF A TRIAL.....	21
4.13	FINAL REPORT(S) BY INVESTIGATOR.....	21
<b>5.</b>	<b>SPONSOR .....</b>	<b>21</b>
5.1	QUALITY ASSURANCE AND QUALITY CONTROL.....	21
5.2	CONTRACT RESEARCH ORGANIZATION (CRO) .....	22
5.3	MEDICAL EXPERTISE.....	22
5.4	TRIAL DESIGN .....	22
5.5	TRIAL MANAGEMENT, DATA HANDLING, AND RECORD KEEPING.....	22
5.6	INVESTIGATOR SELECTION .....	24
5.7	ALLOCATION OF RESPONSIBILITIES .....	24
5.8	COMPENSATION TO SUBJECTS AND INVESTIGATORS .....	24
5.9	FINANCING .....	24
5.10	NOTIFICATION/SUBMISSION TO REGULATORY AUTHORITY(IES) .....	24

5.11	CONFIRMATION OF REVIEW BY IRB/IEC.....	25
5.12	INFORMATION ON INVESTIGATIONAL PRODUCT(S) .....	25
5.13	MANUFACTURING, PACKAGING, LABELLING, AND CODING INVESTIGATIONAL PRODUCT(S).....	25
5.14	SUPPLYING AND HANDLING INVESTIGATIONAL PRODUCT(S) .....	26
5.15	RECORD ACCESS .....	26
5.16	SAFETY INFORMATION.....	27
5.17	ADVERSE DRUG REACTION REPORTING .....	27
5.18	MONITORING .....	27
5.19	AUDIT .....	29
5.20	NONCOMPLIANCE .....	30
5.21	PREMATURE TERMINATION OR SUSPENSION OF A TRIAL .....	30
5.22	CLINICAL TRIAL/STUDY REPORTS .....	30
5.23	MULTICENTRE TRIALS.....	30
<b>6.</b>	<b>CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S) .....</b>	<b>31</b>
6.1	GENERAL INFORMATION.....	31
6.2	BACKGROUND INFORMATION .....	31
6.3	TRIAL OBJECTIVES AND PURPOSE.....	31
6.4	TRIAL DESIGN .....	32
6.5	SELECTION AND WITHDRAWAL OF SUBJECTS .....	32
6.6	TREATMENT OF SUBJECTS .....	32
6.7	ASSESSMENT OF EFFICACY .....	33
6.8	ASSESSMENT OF SAFETY .....	33
6.9	STATISTICS .....	33
6.10	DIRECT ACCESS TO SOURCE DATA/DOCUMENTS .....	33
6.11	QUALITY CONTROL AND QUALITY ASSURANCE .....	33
6.12	ETHICS.....	33
6.13	DATA HANDLING AND RECORD KEEPING .....	34
6.14	FINANCING AND INSURANCE .....	34
6.15	PUBLICATION POLICY .....	34
6.16	SUPPLEMENTS.....	34
<b>7.</b>	<b>INVESTIGATOR'S BROCHURE.....</b>	<b>34</b>
7.1	INTRODUCTION .....	34
7.2	GENERAL CONSIDERATIONS .....	35
7.3	CONTENTS OF THE INVESTIGATOR'S BROCHURE.....	35
7.5	APPENDIX 2:.....	38
<b>8.</b>	<b>ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL.....</b>	<b>39</b>
8.1	INTRODUCTION .....	39
8.2	BEFORE THE CLINICAL PHASE OF THE TRIAL COMMENCES .....	40
8.3	DURING THE CLINICAL CONDUCT OF THE TRIAL .....	44
8.4	AFTER COMPLETION OR TERMINATION OF THE TRIAL .....	48